Key clinical point: Interleukin-23 optimizes antimicrobial macrophage activity, which is reduced in persons harboring an IL-23 receptor variant that helps protect against inflammatory bowel disease.
Major finding: Autocrine/paracrine IL-23 increases bacterial uptake by macrophages and induces faster and more effective clearance of intracellular bacteria. Macrophages from carriers of the IL-23 receptor–Q381 variant, which is protective against inflammatory bowel disease, showed reduced bacterial uptake and less effective intracellular clearance.
Data source: Western blot, flow cytometry, and gentamicin protection assays of human monocyte–derived macrophages.
Disclosures: The National Institutes of Health provided funding. The investigators reported having no conflicts of interest.
Sun R, Abraham C. Cell Molec Gastro Hepatol. 2020 May 28..